fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹310.967 ↓ -4.58  (-1.45 %) as on 24 Sep 21

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 22% since its launch.  Ranked 35 in Sectoral category.  Return for 2020 was 66.4% , 2019 was 1.7% and 2018 was 3.6% .

Below is the key information for Nippon India Pharma Fund

NAV as on 24 Sep 21₹310.967 ↓ -4.58  (-1.45 %)
Net Assets (AUM) as on 31 Aug 2021 ₹5,667 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio4.33
Expense Ratio0.96 %
Sharpe Ratio2.618
Information Ratio1.09
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 24 Sep 21

DurationReturns
1 Month 2.1%
3 Month 4.4%
6 Month 26.4%
1 Year 42.6%
3 Year 25.1%
5 Year 16.2%
10 Year
15 Year
Since launch 22%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%
2013 20.9%
2012 34.8%

Growth of 10k Over Years

DateValue
31 Aug 16₹10,000
31 Aug 17₹8,562
31 Aug 18₹11,233
31 Aug 19₹9,810
31 Aug 20₹14,805
31 Aug 21₹21,906
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash4.77%
Equity95.23%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care95.23%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic10%₹588 Cr7,600,976
↑ 300,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic10%₹540 Cr1,100,000
↓ -50,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | 500124
Drug Manufacturers - Specialty & Generic8%₹452 Cr960,000
Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - General8%₹442 Cr4,800,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
Drug Manufacturers - Specialty & Generic8%₹440 Cr4,800,000
↑ 300,000
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic7%₹377 Cr3,400,025
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
Drug Manufacturers - General6%₹354 Cr900,000
↓ -150,953
Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Aug 18 | 532843
Medical Care Facilities5%₹291 Cr11,590,455
↓ -600,000
Thyrocare Technologies Ltd (Healthcare)
Equity, Since 31 May 16 | THYROCARE
Diagnostics & Research4%₹246 Cr1,883,739
Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP
Medical Care Facilities4%₹242 Cr600,772
↓ -91,000
1 - 10 of 27
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0516.35 Yr.
Kinjal Desai25 May 183.19 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Private Limited
Address"KARVY HOUSE",46, Avenue 4, Street No.1,,Banjara Hills,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹90.2456
↓ -1.33
26.41 %53.86 %27.41 %17.46 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹90.2456
↓ -1.33
26.41 %53.86 %27.41 %17.46 %
Nippon India Pharma Fund
Growth
₹310.967
↓ -4.58
26.41 %42.64 %25.06 %16.16 %
Data as on 24 Sep 21

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.